Design Therapeutics Stock Forecast
NASDAQ: DSGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 9:31 AM ET
DSGN analyst consensus
Consensus (8 analysts)
strong_buy
Avg. price target
$21.71+89.61%
- Strong buy 2
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 8 Wall Street analysts covering Design Therapeutics (2026-10-08), 8 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $21.71, with a high estimate of $26.00 and a low estimate of $20.00. The average target implies upside of 89.6% from the current price of $11.45.
The spread between the highest and lowest targets is 30.0%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for DSGN.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 2 | 25% |
| Buy | 6 | 75% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $20.00 | +74.67% |
| Average target | $21.71 | +89.61% |
| High target | $26.00 | +127.07% |